The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Genomic profiling to predict prognosis for patients with HR-SMM
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, speaks on the use of genomic profiling to analyze temporal changes and predict prognosis in high-risk smoldering multiple myeloma (HR-SMM). In this study, whole-genome sequencing (WGS) was employed to reveal early genomic translocations in HR-SMM that were associated with poor treatment outcomes, with early gains of 1q being a strong predictor of a poor prognosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
